Long-term Omalizumab Therapy in Patients with Chronic Spontaneous Urticaria: Does it Increase the Risk of COVID-19?

Long-term Omalizumab Therapy in Patients with Chronic Spontaneous Urticaria: Does it Increase the Risk of COVID-19?

Introduction: Based on the existing literature, omalizumab (OMZ) is considered a safe treatment modality in chronic spontaneous urticaria (CSU) during the coronavirus disease 19 (COVID-19) era.  Objectives: The aim of this study is to evaluate the effects of OMZ on CSU patients regarding COVID-19...

Full description

Bibliographic Details
Main Authors: Özge Kaya, Zeynep Keskinkaya, Selda Işık Mermutlu, Sevilay Oğuz Kılıç, Sevgi Öztürk
Format: Article
Language:English
Published: Mattioli1885 2023-07-01
Series:Dermatology Practical & Conceptual
Subjects:
angiotensin-converting enzyme 2
chronic spontaneous urticaria
COVID-19
omalizumab
activation
Online Access:http://dpcj.org/index.php/dpc/article/view/2912

Internet

http://dpcj.org/index.php/dpc/article/view/2912

Similar Items